ReviewExpert review of clinical immunology2025
Re-envisioning clinical trial design in systemic sclerosis.
Review in Expert review of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A randomised open-label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot).Rheumatology (Oxford, England) · 2026Trial
- Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies.Rheumatology (Oxford, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionSystemic sclerosis (SSc) is a progressive autoimmune rheumatic disease with high morbidity and mortality and few effective treatment options. Increased biopharmaceutical investment in therapeutic development for rare diseases has created new opportunities for drug discovery in SSc. However, despite the increased pipeline activity in SSc, success rates remain dismally low. AREAS COVERED: This review describes the current state of therapeutic development in SSc with an in-depth coverage of cohort enrichment strategies, as well as a discussion of relevant ethical and feasibility concerns. This review also highlights lessons learned from phase 3 trials in SSc published within the last 5 years in PubMed, underscoring the impact of background therapy on SSc disease course during the trial period. Emerging clinical trial formats and endpoints are also explored. EXPERT OPINION: The authors present recommendations to innovate clinical trial design in SSc, which integrate evidence from recent clinical trial and observational cohort studies in SSc. With a focus on the use of external control arms, the application of adaptive trial design and the development of global disease activity measures, the authors outline practical and ethical solutions to design precise and efficient trials in SSc with a higher probability of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.